- Home
- RMCO vs SCNX Comparison
RMCO vs SCNX Comparison
Compare RMCO & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMCO | SCNX |
|---|---|---|
| Founded | 2021 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Other Pharmaceuticals |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.6M | 16.2M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RMCO | SCNX |
|---|---|---|
| Price | $2.35 | $3.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.1K | ★ 50.3K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | ★ 0.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,949,916.00 | $3,831,778.00 |
| Revenue This Year | $61.62 | $1,009.57 |
| Revenue Next Year | $62.50 | $259.51 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 513.30 | 30.72 |
| 52 Week Low | $1.74 | $3.21 |
| 52 Week High | $5.00 | $106.25 |
Technical Indicators
Market Signals| Indicator | RMCO | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 29.81 | 46.91 |
| Support Level | $2.11 | N/A |
| Resistance Level | $2.46 | $11.68 |
| Average True Range (ATR) | 0.09 | 8.44 |
| MACD | -0.02 | -1.39 |
| Stochastic Oscillator | 0.00 | 0.06 |
Price Performance
Historical ComparisonAbout RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp is formed to invest or purchase assets that have near and medium-term income potential to provide RMC with accretive cash flow from which it can reinvest in new assets or expand cash flow from those existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.